Press release
Gastroparesis Therapeutics Market Size Report 2034 | Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, Cin Dome Pharma, and others.
DelveInsight's "Gastroparesis Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Gastroparesis, historical and forecasted epidemiology as well as the Gastroparesis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.Key Takeaways from the Gastroparesis Market Report
• The total Gastroparesis prevalent cases in the 7MM were around ~7,200,000 cases in 2023 out of which the highest Gastroparesis prevalent cases were seen in the United States.
• Gastroparesis as a disease predominantly affects women, with ~68.5% of the diagnosed patients being females, while only ~31.5% of the diagnosed patients are males.
• As per the DelveInsight estimates, United States has the largest share of diagnosed Gastroparesis cases in the 7MM. These cases are expected to grow with a significant CAGR in the study period 2020-2034.
• The leading Gastroparesis Companies working in the market include Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, Cin Dome Pharma, and others.
• Promising Gastroparesis Pipeline Therapies in the various stages of development include Velusetrag, tadalafil, PCS12852, Naronapride, CIN-102 Dose 1, Metoclopramide Nasal Spray, and others.
Discover which therapies are expecte to grab the Gastroparesis Market Share @ Gastroparesis Market Outlook- https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Gastroparesis Overview
Gastroparesis is a medical condition that affects the normal movement of muscles in the stomach, leading to delayed emptying of food into the small intestine. This delay in digestion can cause various symptoms such as nausea, vomiting, bloating, abdominal pain, feeling full quickly, and changes in blood sugar levels. It's often caused by damage to the vagus nerve, which controls the muscles of the stomach, or by damage to the muscles themselves. It can be associated with conditions like diabetes, neurological diseases, or certain medications. Treatment usually involves dietary changes, medication to stimulate stomach emptying, and in severe cases, surgery may be necessary.
Gastroparesis Epidemiology Segmentation in the 7MM
• Gastroparesis Prevalent cases
• Gastroparesis Gender-specific Diagnosed cases
• Gastroparesis Cause-specific Diagnosed cases
• Gastroparesis Treated cases
• Gastroparesis Age-specific Diagnosed Cases
• Gastroparesis Diagnosed Prevalent cases
Download the report to understand which factors are driving Gastroparesis Epidemiology trends @ Gastroparesis Epidemiological Insights- https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Gastroparesis Market Insights
Management of Gastroparesis involves correcting fluid, electrolyte, and nutritional deficiencies, identifying and treating the cause of delayed gastric emptying (for example, diabetes mellitus), and suppressing or eliminating symptoms. Therapeutic strategies rely on dietary modification, medications that stimulate gastric motor activity, antiemetic drug therapy, and nonpharmacological measures such as endoscopic or surgical intervention or gastric electrical stimulation.
Gastroparesis Treatment Landscape
The Gastroparesis treatment is based on the severity of the symptoms of the disease. If diabetes is associated with Gastroparesis, then treatment is done by controlling blood glucose levels. The treatment of gastroparesis mainly includes nonpharmacological steps, such as dietary modification, and pharmacological measures, including medications that stimulate gastric emptying (prokinetics), medications that reduce vomiting (antiemetics), medications for controlling pain and intestinal spasms, and surgery.
To know more about Gastroparesis treatment guidelines, visit @ Gastroparesis Treatment Market Landscape- https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Gastroparesis Marketed Therapies
• GIMOTI (metoclopramide) Nasal Spray: Evoke Pharma
Metoclopramide hydrochloride, the active ingredient in GIMOTI, is a dopamine-2 receptor antagonist. GIMOTI, a dopamine antagonist/mixed 5-HT3 antagonist/5-HT4 agonist with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis.
Gastroparesis Emerging Therapies
• VLY-686 (tradipitant): Vanda Pharmaceuticals
• PCS12852: Processa Pharmaceuticals
Major Gastroparesis Companies
Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, Cin Dome Pharma, and others.
Learn more about the FDA-approved drugs for Gastroparesis @ Drugs for Gastroparesis Treatment- https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Gastroparesis Market Report
• Coverage- 7MM
• Gastroparesis Companies- Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, Cin Dome Pharma, and others.
• Gastroparesis Therapies- Velusetrag, tadalafil, PCS12852, Naronapride, CIN-102 Dose 1, Metoclopramide Nasal Spray, and others.
• Gastroparesis Market Dynamics: Gastroparesis Market Drivers and Barriers
• Gastroparesis Market Access and Reimbursement, Unmet Needs and Future Perspectives
Discover more about Gastroparesis Drugs in development @ Gastroparesis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Key Insights
2. Report Introduction
3. Executive Summary of Gastroparesis
4. Gastroparesis Market Overview at a Glance
5. Key Events
6. Epidemiology and Market Forecast Methodology
7. Disease Background and Overview
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Therapies
11. Emerging Therapies
12. Gastroparesis: Six Major Market Analysis
13. Unmet Needs
14. SWOT Analysis
15. KOL Views
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gastroparesis Therapeutics Market Size Report 2034 | Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, Cin Dome Pharma, and others. here
News-ID: 3872232 • Views: …
More Releases from DelveInsight Business Research LLP

Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical S …
DelveInsight's "Myelofibrosis Pipeline Insight" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis…

Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Cu …
DelveInsight's "Hemophilia Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia…

DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinica …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive…

Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action …
DelveInsight's "Hearing Loss Pipeline Insight" report provides comprehensive insights about 32+ companies and 35+ pipeline drugs in Hthe earing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights!…
More Releases for Gastroparesis
Top Trends Transforming the Gastroparesis Drugs Market Landscape in 2025: Develo …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Gastroparesis Drugs Industry Market Size Be by 2025?
The market size for drugs treating gastroparesis has significantly increased in the past few years. The progression is predicted to continue from $5.39 billion in 2024 to $5.73 billion in 2025, representing a compound annual growth rate (CAGR)…
Rising Healthcare Expenditure Fuels Growth In The Gastroparesis Market: Transfor …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Gastroparesis Industry Market Size Be by 2025?
In recent times, the gastroparesis market size has been witnessing a consistent growth. It is projected to advance from $6.84 billion in 2024 to $7.17 billion in 2025, registering a compound annual growth rate (CAGR) of 4.9%. Several factors…
Increasing Prevalence Of Diabetes Fuels Growth In The Gastroparesis Drugs Market …
The Gastroparesis Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Gastroparesis Drugs Market?
The gastroparesis drugs market has grown strongly in recent years. It will rise from $5.39 billion in 2024 to $5.73 billion in 2025, at a…
Prominent Gastroparesis Drugs Market Trend for 2025: Development Of Innovative G …
What Are the Projected Growth and Market Size Trends for the Gastroparesis Drugs Market?
In recent times, the gastroparesis drugs market has experienced substantial growth. The market size is projected to expand from $5.39 billion in 2024 to $5.73 billion in 2025, with a compound annual growth rate (CAGR) of 6.3%. Various factors like the side effects associated with current treatments, research into gastrointestinal motility, clinical requirements, patient advocacy efforts and…
Gastroparesis Market Size | Segmentation, Outlook, Industry Report
The Gastroparesis Market was valued at US$ 4,338.61 million in 2019 and is projected to reach US$ 6,025.11 million by 2027; it is expected to grow at a CAGR of 4.3%during 2020-2027.
The growth of the market is mainly attributed to the increasing prevalence of diabetes and growing geriatric population. However, side effects of gastroparesis drugs obstruct the growth of the market.
Get Exclusive Sample PDF @: https://www.premiummarketinsights.com/sample/TIP00024714?utm_source=OpenPr&utm_medium=10640
Analysis of the Top Market…
Gastroparesis Market - Transforming lives through comprehensive gastroparesis tr …
Newark, New Castle, USA: The "Gastroparesis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Gastroparesis Market: https://www.growthplusreports.com/report/gastroparesis-market/8691
This latest report researches the industry structure, sales, revenue, price and…